SCHEMBL2885655

SCHEMBL2885655

CCOC(=O)c1nc(C#N)c2c(ccn2Cc2cccc(OC)c2)c1OC(C)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 1/20 0.42
PTGER2 P43116 1/20 0.42
ELANE P08246 2/20 0.40
ADORA2A P29274 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAOB P27338 3/20 0.39
POLB P06746 2/20 0.39
HTR6 P50406 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
ALDH1A1 P00352 4/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KDM4E B2RXH2 4/20 0.38
MAPT P10636 3/20 0.38
MEN1 O00255 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2886884 0.90 SMN1; SMN2 (0.38) SMN1; SMN2POLBALDH1A1NPSR1KDM4E
SCHEMBL2885817 0.89 POLB (0.40) ELANEADORA2ASMN1; SMN2POLBRXFP1
SCHEMBL2884725 0.89 EGLN1 (0.44) SMN1; SMN2POLBALDH1A1KDM4EMEN1
SCHEMBL2883345 0.88 PTGER4 (0.44) PTGER4PTGER2ELANEADORA2ASMN1; SMN2
SCHEMBL2884011 0.85 MDM2 (0.37) SMN1; SMN2POLBRXFP1ALDH1A1KDM4E
SCHEMBL2885998 0.85 POLB (0.39) PTGER4PTGER2ELANEADORA2APOLB
SCHEMBL2883288 0.84 MAPT (0.38) ELANESMN1; SMN2POLBRXFP1ALDH1A1
SCHEMBL2885564 0.80 SMN1; SMN2 (0.40) ELANESMN1; SMN2POLBRXFP1ALDH1A1
SCHEMBL2880287 0.79 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1KDM4EMAPTHPGD
SCHEMBL2880344 0.78 GRM2 (0.36) ELANESMN1; SMN2ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124489-B1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2020-07-15 EP disclosed
EP-3124489-A1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS Fibrogen, Inc. (US) 2017-02-01 EP disclosed
EP-2016078-B1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2016-06-15 EP disclosed
US-7696223-B2 [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) FIBROGEN, INC. (US) 2010-04-13 US disclosed
EP-2016078-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2009-01-21 EP disclosed
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. 2008-01-03 US disclosed
WO-2007115315-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 PTGER4 1688/4885PTGER2 1929/4885ELANE 3999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.